Skip to main content

Executive Committee

As of November 27, 2017, the Executive Committee of Fagron is composed as follows:

Rafael Padilla
(1978, Spain) - Chief Executive Officer

Rafael Padilla is Chief Executive Officer of Fagron. Rafael graduated from the University of Barcelona in Pharmaceutical Sciences and later completed the post-graduate program for management development (PMD) at IESE Business School. He started working as a pharmacist for Fagron in the Netherlands in 2002. In 2010 he became responsible for the activities of Fagron in South America and Southern Europe. In November 2017, Rafael was appointed CEO of Fagron.

Karin de Jong
(1979, the Netherlands) - Chief Financial Officer

Karin de Jong is the Chief Financial Officer of Fagron. After graduating in Business Administration, Accounting & Control, Karin completed the post-graduate Register Controller degree at Erasmus University. She has been working for Fagron since 2008, where she started as Business Controller. In 2013 she was appointed Group Controller. In 2016 she was appointed CFO of Fagron.

Constantijn van Rietschoten
(1970, the Netherlands) - Chief Communications Officer

Constantijn has studied Politics & Public Administration at Erasmus University. He started working for Fagron in 2008 as Director Investor Relations. From 2012 till 2016 he was responsible for the Global Marketing and Innovation department of Fagron. As from February 2017 he is responsible for Corporate Communications and the activities of Fagron in Australia and South-Africa.

Rita Hoke
President of Fagron North America

Mrs. Hoke is a pharmacist and started her career at Baxter Healthcare, a leading American healthcare company, where she worked in roles of increasing responsibility across multiple functions. From 2004 until 2011, she was responsible for the hospital division in the United States for Grifols, a Spanish multinational active in healthcare and bioscience. Since 2011, she has been active as an advisor for multinationals that are or want to become active in the compounding business in the United States.